These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 8825197)

  • 1. The 3-hydroxypyridin-4-ones more effectively chelate aluminum in a rabbit model of aluminum intoxication than does desferrioxamine.
    Yokel RA; Meurer KA; Skinner TL; Fredenburg AM
    Drug Metab Dispos; 1996 Jan; 24(1):105-11. PubMed ID: 8825197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short-term oral 3-hydroxypyridin-4-one dosing increases aluminum excretion and partially reverses aluminum-induced toxicity in the rabbit independent of chelator lipophilicity.
    Yokel RA; Meurer KA; Hong CB; Dickey KM; Skinner TL; Fredenburg AM
    Drug Metab Dispos; 1997 Feb; 25(2):182-90. PubMed ID: 9029049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention and treatment of aluminum toxicity including chelation therapy: status and research needs.
    Yokel RA; Ackrill P; Burgess E; Day JP; Domingo JL; Flaten TP; Savory J
    J Toxicol Environ Health; 1996 Aug; 48(6):667-83. PubMed ID: 8772805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aluminum chelation by 3-hydroxypyridin-4-ones in the rat demonstrated by microdialysis.
    Yokel RA
    Biol Trace Elem Res; 1996; 53(1-3):193-203. PubMed ID: 8862748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of desferrioxamine on tissue aluminum concentration and bone histology in aluminum-loaded rats with renal failure.
    Verbeelen D; Smeyers-Verbeke J; van Hooff I; de Roy G
    J Trace Elem Electrolytes Health Dis; 1988 Jun; 2(2):67-72. PubMed ID: 2980801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of potential aluminum chelators in vitro by aluminum solubilization ability, aluminum mobilization from transferrin and the octanol/aqueous distribution of the chelators and their complexes with aluminum.
    Yokel RA; Datta AK; Jackson EG
    J Pharmacol Exp Ther; 1991 Apr; 257(1):100-6. PubMed ID: 2019981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chelating effect of novel pyrimidines in a model of aluminum intoxication.
    Missel JR; Schetinger MR; Gioda CR; Bohrer DN; Pacholski IL; Zanatta N; Martins MA; Bonacorso H; Morsch VM
    J Inorg Biochem; 2005 Sep; 99(9):1853-7. PubMed ID: 16098596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aluminum chelation: chemistry, clinical, and experimental studies and the search for alternatives to desferrioxamine.
    Yokel RA
    J Toxicol Environ Health; 1994 Feb; 41(2):131-74. PubMed ID: 8301696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro and in vivo comparative studies on chelation of aluminum by some polyaminocarboxylic acids.
    Graff L; Muller G; Burnel D
    Res Commun Mol Pathol Pharmacol; 1995 Jun; 88(3):271-92. PubMed ID: 8564384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined chelation based on glycosyl-mono- and bis-hydroxypyridinones for aluminium mobilization: solution and biodistribution studies.
    Chaves S; Dron PI; Danalache FA; Sacoto D; Gano L; Santos MA
    J Inorg Biochem; 2009 Nov; 103(11):1521-9. PubMed ID: 19748126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of the chelator desferrioxamine on aluminum elimination in rabbits.
    Melograna JM; Yokel RA
    Res Commun Chem Pathol Pharmacol; 1983 Jun; 40(3):497-509. PubMed ID: 6622822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chelator-facilitated removal of iron from transferrin: relevance to combined chelation therapy.
    Devanur LD; Evans RW; Evans PJ; Hider RC
    Biochem J; 2008 Jan; 409(2):439-47. PubMed ID: 17919118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Removal of thallium by combining desferrioxamine and deferiprone chelators in rats.
    Amiri A; Fatemi SJ; Fatemi SN
    Biometals; 2007 Apr; 20(2):159-63. PubMed ID: 16927173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reversal by desferrioxamine of tau protein aggregates following two days of treatment in aluminum-induced neurofibrillary degeneration in rabbit: implications for clinical trials in Alzheimer's disease.
    Savory J; Huang Y; Wills MR; Herman MM
    Neurotoxicology; 1998 Apr; 19(2):209-14. PubMed ID: 9553957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of aluminum 3-hydroxypyridin-4-one complexes: implications for aluminum redistribution subsequent to chelation therapy.
    Allen DD; Orvig C; Yokel RA
    Toxicology; 1994 Sep; 92(1-3):193-202. PubMed ID: 7940560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative aluminum mobilizing actions of deferoxamine and four 3-hydroxypyrid-4-ones in aluminum-loaded rats.
    Gómez M; Esparza JL; Domingo JL; Singh PK; Jones MM
    Toxicology; 1998 Sep; 130(2-3):175-81. PubMed ID: 9865484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Desferrioxamine in the treatment of aluminum overload.
    Ackrill P; Day JP
    Clin Nephrol; 1985; 24 Suppl 1():S94-7. PubMed ID: 3842106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New tripodal hydroxypyridinone based chelating agents for Fe(III), Al(III) and Ga(III): Synthesis, physico-chemical properties and bioevaluation.
    Grazina R; Gano L; Sebestík J; Amelia Santos M
    J Inorg Biochem; 2009 Feb; 103(2):262-73. PubMed ID: 19062099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of potential aluminum chelators in an octanol/aqueous system and in the aluminum-loaded rabbit.
    Yokel RA; Kostenbauder HB
    Toxicol Appl Pharmacol; 1987 Nov; 91(2):281-94. PubMed ID: 3672527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro and in vivo evaluation of potential aluminum chelators.
    Graff L; Muller G; Burnel D
    Vet Hum Toxicol; 1995 Oct; 37(5):455-61. PubMed ID: 8592836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.